Clinical reference Biomarker Directory
Back to directory

Iduronate-2-Sulfatase

Established

Iduronate-2-sulfatase deficiency causes Hunter syndrome, now part of expanded US newborn screening since 2022.

Also known as I2S IDS enzyme
In plain language

This enzyme breaks down certain sugars in the body; without enough of it, a serious inherited condition called Hunter syndrome develops. Newborn screening for this was recently expanded nationally, catching cases early enough that treatment can start before permanent damage occurs.

Biomarker & context

Iduronate-2-sulfatase (I2S) is a lysosomal enzyme required to break down glycosaminoglycans; its deficiency causes mucopolysaccharidosis type II (MPS II, Hunter syndrome), an X-linked progressive multisystem disorder.

What it indicates

Low I2S enzyme activity confirms Hunter syndrome, which causes coarse facial features, organ enlargement, skeletal abnormalities, and in severe cases, progressive cognitive decline; early identification allows treatment before irreversible organ damage.

Diagnosis & clinical testing

Screened via dried blood spot enzyme activity assay (newborn screening) or diagnostic testing in symptomatic patients; MPS II was added to the US Recommended Uniform Screening Panel for newborns in August 2022, expanding screening beyond the handful of states that had adopted it earlier.

Guiding treatment

Enzyme replacement therapy (idursulfase) is the FDA-approved treatment; a complicating wrinkle from recent newborn screening data is that some genetic variants are associated with abnormally low enzyme activity but no actual disease symptoms even into adulthood, raising open questions about how to counsel these families.

Clinical significance

Newborn screening has identified some variants with abnormal biochemistry but no clinical disease, an evolving area.

References
  1. PMC. (2022). Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States.
  2. PMC. (2025). Novel Phenotypic Insights into the IDS c.817C>T Variant in MPS II from Newborn Screening Cohorts.